Unlearn.AI nabs $12M to build “Digital Twins” to speed up and improve clinical trials

Twins have long played a role in the world of medical research, specifically in the area of clinical trials, where they can help measure the effectiveness of a therapy by applying a control to one of a genetically-similar pair. Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI, which has built a machine learning platform that builds “digital twin” profiles of patients that become the controls in clinical trials — is announcing that it has raised $12 million in a Series A round.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Announcing The Unlearn Opportunities Internship Program

Podcasts

UCSF Rosenman Institute - The Health Technology Podcast #59: Digital Twins for Clinical Trials

Podcasts

The Health-Tech Podcast #111: The Story of Unlearn.ai with Charles Fisher

The Health-Tech Podcast covers the latest in health and technology through interviews with disruptive health-tech startups and leaders.
Charles Fisher: Digital Twins for Clinical Trials
Creating Opportunities for Students of Data Science and Business from Underrepresented Groups in STEM